{
    "eid": "2-s2.0-84904299123",
    "title": "The tyrosine kinase inhibitor dasatinib effectively blocks PDGF-induced orbital fibroblast activation",
    "cover-date": "2014-01-01",
    "subject-areas": [
        {
            "$": "Cellular and Molecular Neuroscience",
            "@code": "2804"
        },
        {
            "$": "Sensory Systems",
            "@code": "2809"
        },
        {
            "$": "Ophthalmology",
            "@code": "2731"
        }
    ],
    "keywords": [
        "Dasatinib",
        "Graves' Ophthalmopathy",
        "Imatinib mesylate",
        "Tyrosine kinase inhibitor"
    ],
    "authors": [
        "Sita Virakul"
    ],
    "citedby-count": 17,
    "ref-count": 23,
    "ref-list": [
        "Graves' disease",
        "Prevalence and natural history of graves' orbitopathy in a large series of patients with newly diagnosed graves' hyperthyroidism seen at a single center",
        "Graves' ophthalmopathy",
        "Randomized, single blind trial of intravenous versus oral steroid monotherapy in graves' orbitopathy",
        "The effect of etanercept on Graves' ophthalmopathy: A pilot study",
        "Infliximab: A novel treatment for sight-threatening thyroid associated ophthalmopathy",
        "Potential utility of rituximab for graves' orbitopathy",
        "83rd Annual Meeting of the American Thyroid Association, San Juan, Puerto Rico 2013",
        "Role of platelet-derived growth factors in physiology and medicine",
        "Platelet-derived growth factor-BB: A stimulus for cytokine production by orbital fibroblasts in graves' ophthalmopathy",
        "Imatinib mesylate and AMN107 inhibit PDGF-signaling in orbital fibroblasts: A potential treatment for Graves' ophthalmopathy",
        "Orbit-infiltrating mast cells, monocytes, and macrophages produce PDGF isoforms that orchestrate orbital fibroblast activation in graves' ophthalmopathy",
        "Activity-based kinase profiling of approved tyrosine kinase inhibitors",
        "Whole orbital tissue culture identifies imatinib mesylate and adalimumab as potential therapeutics for Graves' ophthalmopathy",
        "Peripheral artery occlusive disease in chronic phase chronic myeloid leukemia patients treated with nilotinib or imatinib",
        "The development of dasatinib as a treatment for chronic myeloid leukemia (CML): From initial studies to application in newly diagnosed patients",
        "Long-term outcome with dasatinib after imatinib failure in chronic-phase chronic myeloid leukemia: Follow-up of a phase 3 study",
        "Dual inhibition of c-abl and PDGF receptor signaling by dasatinib and nilotinib for the treatment of dermal fibrosis",
        "The tyrosine kinase inhibitor dasatinib suppresses cytokine production by plasmacytoid dendritic cells by targeting endosomal transport of CpG DNA",
        "PDGF enhances orbital fibroblast responses to TSHR stimulating autoantibodies in Graves' ophthalmopathy patients",
        "Therapeutic Inhibition of Tyrosine Kinases in Systemic Sclerosis: A Review of Published Experience on the First 108 Patients Treated with Imatinib",
        "Early response with dasatinib or imatinib in chronic myeloid leukemia: 3-year follow-up from a randomized phase 3 trial (DASISION)",
        "Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia"
    ],
    "affiliation": [
        {
            "affiliation-city": "Rotterdam",
            "affilname": "Erasmus MC",
            "affiliation-country": "Netherlands"
        },
        {
            "affiliation-city": "Rotterdam",
            "affilname": "Rotterdam Eye Hospital",
            "affiliation-country": "Netherlands"
        },
        {
            "affiliation-city": "Geneva",
            "affilname": "H\u00f4pitaux Universitaires de Gen\u00e8ve",
            "affiliation-country": "Switzerland"
        },
        {
            "affiliation-city": "Bangkok",
            "affilname": "Faculty of Medicine, Chulalongkorn University",
            "affiliation-country": "Thailand"
        }
    ],
    "funding": []
}